An efficient and straightforward synthesis ofberaprost sodium was developed with dicyclopentadiene as a starting material, a one-pot reaction product 5 as key intermediate and the Prins reaction and the Homer-Wadswort...An efficient and straightforward synthesis ofberaprost sodium was developed with dicyclopentadiene as a starting material, a one-pot reaction product 5 as key intermediate and the Prins reaction and the Homer-Wadsworth-Emmons reaction as key steps. The structures of the key intermediate and the target compound were confirmed by 1H NMR, 13C NMR and MS. The purity of beraprost sodium identified by high performance liquid chromatography（HPLC） was identical to that of Japanese Pharmacopoeia（16th）. This development will be used for the industrial synthesis of beraprost sodium.展开更多
目的系统评价中药联合贝前列素钠治疗下肢动脉硬化闭塞症的临床疗效及安全性。方法计算机检索PubMed、Web of Science、Cochrane Library、MEDLINE、中国生物医学文献服务系统、知网、万方和维普等数据库采用中药联合贝前列素钠治疗下...目的系统评价中药联合贝前列素钠治疗下肢动脉硬化闭塞症的临床疗效及安全性。方法计算机检索PubMed、Web of Science、Cochrane Library、MEDLINE、中国生物医学文献服务系统、知网、万方和维普等数据库采用中药联合贝前列素钠治疗下肢动脉硬化闭塞症的临床对照研究。检索时限均为从建库至2023年3月15日。由2名研究者独立筛选文献并评价,运用Rev-Man统计软件分析。结果共纳入12篇文献,共计1129例。meta分析结果显示,中药联合贝前列素钠治疗下肢动脉硬化闭塞症在临床有效率方面优势明显[RR=1.20,95%CI(1.13,1.27),P<0.00001],改善患者踝肱指数[SMD=0.15,95%CI(0.01,0.29),P=0.03],增加足背动脉血流量[MD=5.31,95%CI(1.08,9.54),P=0.01]、行走距离[MD=72.49,95%CI(30.39,114.60),P=0.0007]。结论中药内服联合贝前列素钠可提高下肢动脉硬化闭塞症临床疗效优于单独使用贝前列素钠。展开更多
文摘An efficient and straightforward synthesis ofberaprost sodium was developed with dicyclopentadiene as a starting material, a one-pot reaction product 5 as key intermediate and the Prins reaction and the Homer-Wadsworth-Emmons reaction as key steps. The structures of the key intermediate and the target compound were confirmed by 1H NMR, 13C NMR and MS. The purity of beraprost sodium identified by high performance liquid chromatography（HPLC） was identical to that of Japanese Pharmacopoeia（16th）. This development will be used for the industrial synthesis of beraprost sodium.
文摘目的系统评价中药联合贝前列素钠治疗下肢动脉硬化闭塞症的临床疗效及安全性。方法计算机检索PubMed、Web of Science、Cochrane Library、MEDLINE、中国生物医学文献服务系统、知网、万方和维普等数据库采用中药联合贝前列素钠治疗下肢动脉硬化闭塞症的临床对照研究。检索时限均为从建库至2023年3月15日。由2名研究者独立筛选文献并评价,运用Rev-Man统计软件分析。结果共纳入12篇文献,共计1129例。meta分析结果显示,中药联合贝前列素钠治疗下肢动脉硬化闭塞症在临床有效率方面优势明显[RR=1.20,95%CI(1.13,1.27),P<0.00001],改善患者踝肱指数[SMD=0.15,95%CI(0.01,0.29),P=0.03],增加足背动脉血流量[MD=5.31,95%CI(1.08,9.54),P=0.01]、行走距离[MD=72.49,95%CI(30.39,114.60),P=0.0007]。结论中药内服联合贝前列素钠可提高下肢动脉硬化闭塞症临床疗效优于单独使用贝前列素钠。
